We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+30.06%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$969M
AUM Growth
+$203M
Cap. Flow
+$35.5M
Cap. Flow %
3.66%
Top 10 Hldgs %
91.64%
Holding
30
New
3
Increased
5
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$48.2M
2
IVA
Inventiva
IVA
+$24.1M
3
RANI icon
Rani Therapeutics
RANI
+$12.8M
4
KLRS
Kalaris Therapeutics
KLRS
+$9.59M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$7.12M

Top Sells

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$16M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$15.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$10.3M
4
PVLA
Palvella Therapeutics
PVLA
+$8.94M
5
CTNM
Contineum Therapeutics
CTNM
+$5.69M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
26
Surrozen
SRZN
$301M
– –
-241,400
Closed -$3.11M
SRZNW icon
27
Surrozen Inc Warrant
SRZNW
$8.86K
– –
-99,999
Closed -$1.78K
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
– –
-135,573
Closed -$1.02M
ZYME icon
29
Zymeworks
ZYME
$1.67B
– –
-207,901
Closed -$3.55M
LENZ
30
LENZ Therapeutics
LENZ
$168M
– –
-343,012
Closed -$16M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2025 Portfolio in Review

As of Q4 2025, Samsara BioCapital held 30 positions worth $969M, up 27% from $766M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Samsara BioCapital deployed $35.5M of net new capital in Q4 2025, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Inventiva: 5,194,805 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $15.7M trimmed.

  • Samsara BioCapital's largest Q4 2025 buy was Inventiva: 5,194,805 shares worth $24.2M.
  • Samsara BioCapital added most to Scholar Rock in Q4 2025, an estimated $48.2M increase.
  • Samsara BioCapital's biggest Q4 2025 reduction was Mineralys Therapeutics, cutting an estimated $15.7M.
  • Samsara BioCapital fully exited LENZ Therapeutics in Q4 2025, selling an estimated $16M.
  • Samsara BioCapital's ten largest holdings make up 92% of its $969M portfolio in Q4 2025.
  • Samsara BioCapital opened 3 new positions and closed 9 in Q4 2025.
  • Samsara BioCapital's portfolio value rose 27% quarter-over-quarter to $969M.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.